Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6356462 | 0.79 | — | — | |
| SCHEMBL3840247 | 0.78 | HRH3 (0.42) | HRH3ALDH1A1MAPK1PARP1PKM | |
| SCHEMBL2037718 | 0.78 | HRH3 (0.42) | HRH3ALDH1A1MAPK1PARP1PKM | |
| SCHEMBL9939121 | 0.77 | HRH3 (0.39) | HRH3ALDH1A1MAPK1PARP1PKM | |
| SCHEMBL8434648 | 0.76 | HRH3 (0.46) | HRH3ALDH1A1MAPK1PARP1PKM | |
| SCHEMBL3846855 | 0.76 | HRH3 (0.41) | HRH3ALDH1A1MAPK1PARP1PKM | |
| SCHEMBL5446824 | 0.76 | HRH3 (0.41) | HRH3ALDH1A1MAPK1PARP1PKM | |
| Hydrochloric Acid SCHEMBL14743464 | 0.76 | HRH3 (0.41) | HRH3ALDH1A1MAPK1PARP1PKM | |
| SCHEMBL10439336 | 0.76 | GPR84 (0.49) | HRH3ALDH1A1MAPK1PARP1PKM | |
| SCHEMBL3841613 | 0.76 | HRH3 (0.41) | HRH3ALDH1A1MAPK1PARP1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | RENOVIS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-6008372-A | ANTICARCINOGENIC, ANTIRESTENOSIS AND ANTIPSORIASIS AGENT | WARNER-LAMBERT COMPANY (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1997026246-A1 | SUBSTITUTED HISTIDINE INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1997-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | PARK7, UACA, PTGER4 | HRH3 781/4885ALDH1A1 1289/4885MAPK1 1996/4885 |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | HRH3 1013/4885ALDH1A1 3640/4885MAPK1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.